Influence of Lipid Composition of Cationic Liposomes 2X3-DOPE on mRNA Delivery into Eukaryotic Cells.
cationic lipids
liposomes
mRNA
non-viral delivery systems
transfection
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
20 Dec 2022
20 Dec 2022
Historique:
received:
18
11
2022
revised:
08
12
2022
accepted:
13
12
2022
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
The design of cationic liposomes for efficient mRNA delivery can significantly improve mRNA-based therapies. Lipoplexes based on polycationic lipid 1,26-bis(cholest-5-en-3β-yloxycarbonylamino)-7,11,16,20-tetraazahexacosane tetrahydrochloride (2X3) and helper lipid 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) were formulated in different molar ratios (1:1, 1:2, 1:3) to efficiently deliver model mRNAs to BHK-21 and A549. The objective of this study was to examine the effect of 2X3-DOPE composition as well as lipid-to-mRNA ratio (amino-to-phosphate group ratio, N/P) on mRNA transfection. We found that lipoplex-mediated transfection efficiency depends on both liposome composition and the N/P ratio. Lipoplexes with an N/P ratio of 10/1 showed nanometric hydrodynamic size, positive ζ potential, maximum loading, and transfection efficiency. Liposomes 2X3-DOPE (1:3) provided the superior delivery of both mRNA coding firefly luciferase and mRNA-eGFP into BHK-21 cells and A549 cells, compared with commercial Lipofectamine MessengerMax.
Identifiants
pubmed: 36678637
pii: pharmaceutics15010008
doi: 10.3390/pharmaceutics15010008
pmc: PMC9860636
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministry of Health of the Russian Federation
ID : 056-00112-22-03
Organisme : the Ministry of Science and Higher Education of the Russian Federation under the strategic aca-demic leadership program "Priority 2030"
ID : 075-15-2021-1333
Organisme : the Ministry of Science and Higher Education of the Russian Federation under the strategic aca-demic leadership program "Priority 2030"
ID : 075-15-2021-1190
Références
Molecules. 2018 Nov 27;23(12):
pubmed: 30486442
Trends Pharmacol Sci. 2020 Oct;41(10):755-775
pubmed: 32893005
Biochim Biophys Acta. 2013 Feb;1828(2):412-8
pubmed: 23092705
J Control Release. 2012 Jun 10;160(2):200-10
pubmed: 22155599
Pharmaceutics. 2021 Apr 14;13(4):
pubmed: 33919859
Adv Drug Deliv Rev. 2020;154-155:37-63
pubmed: 32526452
Pharmaceutics. 2022 Mar 07;14(3):
pubmed: 35335957
Chem Phys Lipids. 1986 Jun-Jul;40(2-4):109-25
pubmed: 3742669
J Control Release. 2006 Nov 28;116(2):255-64
pubmed: 16914222
Colloids Surf B Biointerfaces. 2009 Aug 1;72(1):1-5
pubmed: 19395245
Curr Opin Biotechnol. 2022 Feb;73:329-336
pubmed: 34715546
PLoS One. 2016 Mar 16;11(3):e0150751
pubmed: 26981617
J Control Release. 2012 Jun 10;160(2):182-93
pubmed: 22138073
J Colloid Interface Sci. 2022 Dec;627:283-298
pubmed: 35853406
Biochim Biophys Acta. 2000 Sep 29;1468(1-2):396-402
pubmed: 11018682
ACS Nano. 2019 Apr 23;13(4):3754-3782
pubmed: 30908008
Int J Pharm. 2021 May 15;601:120586
pubmed: 33839230
Sci Rep. 2014 Nov 19;4:7107
pubmed: 25407686
Biochim Biophys Acta. 1995 May 4;1235(2):289-95
pubmed: 7756337
Nat Rev Genet. 2022 May;23(5):265-280
pubmed: 34983972
Molecules. 2020 Oct 28;25(21):
pubmed: 33126767
Pharmaceutics. 2019 Apr 15;11(4):
pubmed: 30991703
N Engl J Med. 2018 Jul 5;379(1):11-21
pubmed: 29972753
Gene Ther. 1995 Dec;2(10):710-22
pubmed: 8750010
Mol Pharm. 2022 Apr 4;19(4):1047-1058
pubmed: 35238565
Int J Pharm. 2010 May 10;390(2):198-207
pubmed: 20116418
Biochim Biophys Acta. 1998 Jan 5;1368(1):115-28
pubmed: 9459590